Scarica l'app Stockscreener
2.94
6.07%
-0.19
Dopo l'orario di chiusura:
2.99
0.05
+1.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Precedente Chiudi:
$3.13
Aprire:
$3.2
Volume 24 ore:
3.79M
Relative Volume:
0.86
Capitalizzazione di mercato:
$880.05M
Reddito:
$38.03M
Utile/perdita netta:
$-146.40M
Rapporto P/E:
-5.6538
EPS:
-0.52
Flusso di cassa netto:
$-121.38M
1 W Prestazione:
+5.76%
1M Prestazione:
-34.96%
6M Prestazione:
-31.15%
1 anno Prestazione:
-5.16%
Intervallo 1D:
$2.93
$3.20
Intervallo di 1 settimana:
$2.8801
$3.28
Portata 52W:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Nome
Abcellera Biologics Inc
Settore
Industria
Telefono
(604) 559-9005
Indirizzo
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.94 | 936.92M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Ripresa | Leerink Partners | Outperform |
| 2024-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Ripresa | Piper Sandler | Overweight |
| 2023-02-28 | Iniziato | Cowen | Outperform |
| 2022-12-15 | Iniziato | Goldman | Buy |
| 2022-11-16 | Iniziato | Truist | Buy |
| 2021-12-21 | Iniziato | The Benchmark Company | Buy |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-01-05 | Iniziato | Berenberg | Buy |
| 2021-01-05 | Iniziato | Credit Suisse | Outperform |
| 2021-01-05 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | Stifel | Buy |
Mostra tutto
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
State of Michigan Retirement System Acquires 350,775 Shares of AbCellera Biologics Inc. $ABCL - MarketBeat
Is AbCellera’s Biotech Platform Setting New Standards for Pharmaceutical Innovation - Kalkine Media
Painful Week for Individual Investors Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) After 10% Drop, Institutions Also Suffered Losses - 富途牛牛
Travel Stocks: Is Lifeway Foods Inc forming a double bottom2025 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Investing News Network
Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions? - Sahm
Short sales on the TSX: What bearish investors are betting against - The Globe and Mail
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
What does Wall Street think about AbCellera Biologics Inc. (ABCL)? - MSN
AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap - Yahoo Finance
AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns - Yahoo Finance
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - Sahm
Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Yahoo Finance
What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? - Insider Monkey
Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn
Strategic Moves Shape ABCL’s Market Position - StocksToTrade
AbCellera’s Market Moves: Key Developments - timothysykes.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat
Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside - DirectorsTalk Interviews
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - PharmiWeb.com
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial - Sahm
AbCellera sets Feb. 24 date to reveal full-year 2025 results - Stock Titan
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st
Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance
AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Investing News Network
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat
AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL6 - PharmiWeb.com
AbCellera (ABCL) Advances Clinical Trial for Menopause Treatment - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade - MarketBeat
Bear Alert: Is AbCellera Biologics Inc stock forming a triangle patternJuly 2025 Drop Watch & Smart Allocation Stock Tips - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Rating Increased to Hold at Wall Street Zen - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After Bruker Settlement And Board Appointment - simplywall.st
Will AbCellera Biologics Inc. stock return to pre crisis levels2025 Pullback Review & Weekly Watchlist of Top Performers - ulpravda.ru
Can AbCellera Biologics Inc. stock maintain operating marginsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
AbCellera Biologics (ABCL) Is Up 20.8% After Bruker Settlement Win And Board AdditionWhat's Changed - simplywall.st
How AbCellera Biologics Inc. stock performs in weak economyJuly 2025 WrapUp & Safe Capital Growth Plans - Улправда
Can AbCellera Biologics Inc. stock hit analyst price targetsMarket Correction Analysis & Maximize Returns With Insights - Улправда
AbCellera (ABCL) Loses Chief Commercial Officer to Viking Therap - GuruFocus
Abcellera Biologics Inc Azioni (ABCL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):